Citadel Advisors
DNTH icon

Citadel Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Citadel Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
31,800
+21,000
+194% +$1.22M ﹤0.01% 5495
2025
Q4 		$445K Sell
10,800
-37,900
-78% -$1.47M ﹤0.01% 9312
2025
Q3 		$1.92M Buy
+48,700
New +$1.24M ﹤0.01% 6155
2025
Q2 		– Sell
-8,900
Closed -$161K – 13054
2025
Q1 		$161K Buy
8,900
+8,300
+1,383% +$183K ﹤0.01% 10752
2024
Q4 		$13.1K Buy
600
+200
+50% +$5.14K ﹤0.01% 13462
2024
Q3 		$11K Buy
+400
New +$11.1K ﹤0.01% 13178
2023
Q2 		– Sell
-431
Closed -$5.48K – 14499
2023
Q1 		$5.48K Buy
431
+181
+72% +$2K ﹤0.01% 13867
2022
Q4 		$1.58K Buy
+250
New +$4.43K ﹤0.01% 14449
2022
Q1 		– Sell
-694
Closed -$49K – 13770
2021
Q4 		$49K Buy
+694
New +$69.8K ﹤0.01% 13260

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's DNTH Position: Q1 2026 in Review

Citadel Advisors increased its Dianthus Therapeutics (DNTH) stake by 51% in Q1 2026, buying an estimated $31.4M and bringing the position to 1,610,483 shares worth $135M. The position accounts for 0.02% of the portfolio, ranked #636.

Citadel Advisors first reported a position in DNTH in Q2 2018 and has held it in 26 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Citadel Advisors held 1,610,483 shares of Dianthus Therapeutics worth $135M as of Q1 2026.
  • Citadel Advisors bought 541,549 Dianthus Therapeutics shares in Q1 2026, an estimated $31.4M.
  • Dianthus Therapeutics made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #636 holding.
  • Citadel Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 26 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.